metaPreg - Trazodone during pregnancy

Trazodone updated on 10-20-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.39 [0.74, 7.73]	26%	4 studies	53,288	73	not evaluable	ROB	-
Major congenital malformations	2.39 [0.74, 7.73]	26%	4 studies	53,288	73	not evaluable	ROB	-
Congenital heart defects	0.81 [0.05, 13.25]	-	1 study	8,107	35	not evaluable	ROB	-
Cleft lip with or without cleft palate	-	-	0 study					-
Cleft palate	-	-	0 study					-
Oro-facial clefts	-	-	0 study					-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	27.94 [0.52, 1494.23]	-	1 study	8	1	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preeclampsia	0.63 [0.38, 1.05]	-	1 study	3,229	339	not evaluable	ROB	-
Postpartum hemorrhage	1.85 [0.90, 3.80]	-	1 study		139	not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal medical care	1.00 [0.02, 53.28]	-	1 study		18	not evaluable	ROB	-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	19.92 [1.21, 328.36]	0%	2 studies	24	2	not evaluable	ROB	39.33 [1.71; .]
Elective/induced termination of pregnancy	17.97 [0.34, 938.20]	-	1 study	14	1	not evaluable	ROB	-
Hide endpoints reported in only one study ...